Hubei Biocause Pharmaceutical (000627.SZ) has submitted an application to the Shenzhen Stock Exchange to terminate its listing.

Hubei Biocause Pharmaceutical (000627.SZ) announced that the company intends to voluntarily withdraw its A-share stocks from the Shenzhen Stock Exchange ("SZSE") through a decision made at a shareholders' meeting, and after delisting from the stock exchange, it will apply to transfer to the National Equities Exchange and Quotations Co., Ltd. ("NEEQ") for management in the delisting transfer section (referred to as "this delisting"). The proposal for this delisting was approved at the company's first extraordinary general meeting of shareholders on August 25, 2025. Based on the above, the company's delisting falls under the category of voluntary delisting as regulated in Article 9.7.1 of the SZSE Stock Listing Rules. Accordingly, the company has submitted the necessary application materials to the SZSE for the voluntary delisting.